Most melanoma patients harbor mutations in the mitogen-activated protein kinase (MAPK) pathway (BRAF-MEK-ERK) (BRAFV600E being the most common) and therefore, benefit from targeted therapies against MAPK pathway (BRAF and MEK inhibitors). Here, BRAF is linked to melanoma.